Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure.

Autor:	Ajay A; Cardiology, Wirral University Teaching Hospital NHS Foundation Trust, Liverpool, UK.; Cardiology, Arrowe Park Hospital, Birkenhead, Wirral, UK., Biju P; Internal Medicine, Countess of Chester Hospital NHS Foundation Trust, Chester, UK.; Intermal medicine, Countess of Chester Health Park, Chester, UK., Ajay H; Internal Medicine, Mersey and West Lancashire Teaching Hospitals, Southport, UK.; Internal medicine, Southport Hospital, Southport, UK., Tripathi R; Internal Medicine, Countess of Chester Hospital NHS Foundation Trust, Chester, UK.; Intermal medicine, Countess of Chester Health Park, Chester, UK., Lip GYH; Cardiology, Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool, UK.; Cardiology, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.; Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Sankaranarayanan R; Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.; Cardiology, Liverpool Centre for Cardiovascular Science and University of Liverpool, Liverpool, UK.
Jazyk:	angličtina
Zdroj:	Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2024 Dec; Vol. 33 (12), pp. 1209-1218. Date of Electronic Publication: 2024 Dec 13.
DOI:	10.1080/13543784.2024.2438663
Abstrakt:	Introduction: Acute failure is a critical condition, encompassed by the sudden or progressive onset of symptoms or signs of congestion. The treatment strategies available are mainly supportive and do not improve mortality or long-term outcomes. Therefore, there is a need for alternative novel treatment strategies. In this narrative review, we explore the role of relaxin agonist as a potential therapeutic strategy in acute heart failure. Areas Covered: We aim to provide an overview of the evidence of preclinical and clinical studies on relaxin as a treatment strategy for acute heart failure. Papers collected in this review are from original research and systematic reviews which have been filtered following Medline and Cochrane Library searches. Expert Opinion: Relaxin has shown great potential in both preclinical and clinical studies due to its antifibrotic, anti-inflammatory, and vasodilatory effect on the heart. However, there has been mixed evidence from clinical trials involving relaxin which could be due to patient groups, investigation sites, trial design, and chance. Further studies should focus on developing biomarkers to identify specific population groups who are most likely to benefit from relaxin.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu